MPD: List measures where strain PWK/PhJ is an outlier

List measures where PWK/PhJ is an outlier

Click on pulldowns below to see PWK/PhJ means with summary statistic tooltips.
Within each pulldown, the "up" and "down" triangles indicate when this strain is an outlier.
You can also download all phenotypes for this strain and sort by Z score in Excel.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Auwerx2:97	Auwerx2	monitoring system	(none)	vertical activity (beam breaks) during day, basal activity test, for 48h [n/h] vert_act_day 114625 CD HFD	inbred w/CC8	9	both	19wks	N=4	2021

Auwerx2:103	Auwerx2	intake monitoring	(none)	daily food intake, basal activity test, averaged over 2 days [g] food_intake 114631 CD HFD	inbred w/CC8	9	both	14wks	N=4	2021

Auwerx2:143	Auwerx2	metabolic panel	(none)	plasma alanine transaminase amount (ALAT) [U/L] ALAT 114671 CD HFD	inbred w/CC8	9	both	21wks	N=4	2021

Auwerx2:151	Auwerx2	metabolic panel	(none)	plasma lactate dehydrogenase amount (LDH) [U/L] LDH 114679 CD HFD	inbred w/CC8	9	both	21wks	N=4	2021

Bachmanov1:1	Bachmanov1	intake monitoring	(none)	water intake [mL] H2O_intake 40401 daily daily adj for body weight	inbred	13	m	7-8wks	N=10	2011

Bachmanov1:4	Bachmanov1	body weight	(none)	body weight [g] bw 40404	inbred	13	m	7-8wks	N=10	2011

CGDpheno1:48	CGDpheno1	lipid profile	(none)	non-esterified free fatty acids (plasma NEFA, FFA) [mEq/L] NEFA 31848	inbred w/CC8	72	both	12wks	N=7	2009

CGDpheno1:60	CGDpheno1	metabolic panel	(none)	total bilirubin (plasma TBIL) [µmol/L] TBIL 31860	inbred w/CC8	72	both	12wks	N=7	2009

CGDpheno1:62	CGDpheno1	metabolic panel	(none)	blood urea nitrogen (BUN) [mg/dL] BUN 31862	inbred w/CC8	72	both	12wks	N=7	2009

Chesler2:15	Chesler2	complete blood count	(none)	monocyte differential (MONO; percentage of viable WBC) [%] pct_MONO 43417	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler2:27	Chesler2	complete blood count	(none)	mean platelet volume (MPV) [fL] MPV 43429	CC diallel w/par	49	both	7-15wks	N=2	2011

Chesler2:28	Chesler2	colony observation	(none)	number of mice born in first litter [n] litter_size 43441	CC diallel w/par	62	both	4wks	N=8	2011

Chesler2:61	Chesler2	body size and weight	(none)	tail length [cm] tail_length 43488	CC diallel w/par	47	both	7-15wks	N=3	2011

Chesler3:29	Chesler3	complete blood count	(none)	mean platelet volume (MPV) [fL] MPV 43529	CC pre w/par	200	both	7-15wks	N=1	2011

Chesler3:88	Chesler3	body size and weight	(none)	tail length [cm] tail_length 43588	CC pre w/par	352	both	7-15wks	N=2	2011

Chesler4:24	Chesler4	nociception assay	(none)	latency of hindpaw withdrawal, 55°C heat stimulation [s] HP_latency 47024	DO population w/par	9	both	12-16wks	N=8	2013

Chesler4:26	Chesler4	tail suspension test	(none)	average frequency climbing, 5 min test [n] TS_frequency_climbing 47026	DO population w/par	9	both	12-16wks	N=8	2013

Churchill1:1	Churchill1	DXA	(none)	whole body bone mineral density (BMD) [g/cm²] body_BMD 17101	F1 8way	63	both	7-8wks	N=5	2004

Churchill1:3	Churchill1	DXA	(none)	vetebral spine bone mineral density (BMD) [g/cm²] spine_BMD 17103	F1 8way	63	both	7-8wks	N=5	2004

Churchill1:4	Churchill1	DXA	(none)	total tissue mass, head excluded [g] tissue_mass 17104	F1 8way	63	both	7-8wks	N=5	2004

Churchill1:6	Churchill1	DXA	(none)	weight of lean tissue, head excluded [g] lean_wt 17106	F1 8way	63	both	7-8wks	N=5	2004

Churchill1:8	Churchill1	organ dimensions	(none)	ear pinal length [mm] ear_length 17108	F1 8way	63	both	7-8wks	N=5	2004

Churchill1:9	Churchill1	muscle weights	(none)	weight of isolated quadriceps muscle [g] quadricep_wt 17109	F1 8way	63	both	7-8wks	N=5	2004

Crowley1:29	Crowley1	behavior observation	haloperidol	tongue protrusions, 15 min test [n] tongue 39429 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

CSNA02:23	CSNA02	bottle choice test	ethanol	ethanol consumption adjusted per kg body weight 'drinking in the dark' [g/kg] EtOH_adj 62223 day 1 day 2 day 3	inbred	18	both	16-39wks	N=6	2018

CSNA02:26	CSNA02	bottle choice test	ethanol	licks on ethanol bottle as a percentage of total licks 'drinking in the dark' [%] EtOH_licks 62226 day 1 day 2 day 3	inbred	18	both	16-39wks	N=5	2018

CSNA03:107	CSNA03	open field test	(none)	time in corners, 60 min test (OFT), CC [s] time_corner_OFT_cc 90107	CC w/par	59	both	4-19wks	N=18	2018

CSNA03:203	CSNA03	light-dark box	(none)	total time, 20 min test (LD box), CC [s] time_tot_LD_cc 90203	CC w/par	59	both	4-19wks	N=18	2018

CSNA03:266	CSNA03	hole board test	(none)	total number of entries (hole board), CC [n] entries_total_HB_cc 90266	CC w/par	59	both	4-19wks	N=18	2018

CSNA03:272	CSNA03	hole board test	(none)	number of repeat entries (hole board), CC [n] entries_repeat_HB_cc 90272	CC w/par	59	both	4-19wks	N=18	2018

CSNA03:289	CSNA03	conditioned place preference test	(none)	percentage of time spent in novel zone, including center gray zone (novelty preference), founders [%] time_w_gray_in 90289	inbred w/CC8	10	both	12wks	N=40	2018

CSNA03:290	CSNA03	conditioned place preference test	(none)	percentage of time spent in novel zone, including center gray zone (novelty preference), CC [%] time_w_gray_cc 90290	CC w/par	59	both	6-14wks	N=17	2018

CSNA03:304	CSNA03	open field test	(none)	distance traveled, last 60 min (post-injection), Day 3 minus Day 2, saline control, founders [cm] dist_d3_d2_cont_in 90304	inbred w/CC8	9	both	8-14wks	N=6	2018

CSNA03:323	CSNA03	open field test	(none)	distance traveled, last 60 min (post-injection), Day 19 minus Day 11, saline control, CC [cm] dist_d19_d11_cont_cc 90323	CC w/par	58	both	8-21wks	N=3	2018

CSNA03:324	CSNA03	open field test	(none)	distance traveled, last 60 min (post-injection), Day 19 minus Day 11, saline control, DO [cm] dist_d19_d11_cont_do 90324	DO population w/par	9	both	8-21wks	N=22	2018

CSNA03:397	CSNA03	open field test	(none)	distance traveled, last 60 min (post-injection), on successive days, saline control, CC [cm] dist_l60_cont_cc 90383 day: 1 2 3 5 7 9 11 12 19	CC w/par	58	both	8-21wks	N=4	2018

CSNA03:424	CSNA03	open field test	cocaine	distance traveled, last 60 min (post-injection), on successive days, cocaine sensitization, CC [cm] dist_l60_cocaine_cc 90386 day: 1 (saline) 2 (saline) 3 5 7 9 11 12 (saline) 19	CC w/par	58	both	8-21wks	N=4	2018

CSNA03:452	CSNA03	operant conditioning chamber	cocaine	dose response, mean number of infusions (intravenous self administration) on last two stabilized sessions, founders [n] infusions_in 110189 mg/kg: 1.0 1.8 0.56 0.32 0.1 0.18 0.056 0.032 1.0 (2nd)	inbred w/CC8	8	both	4-25wks	N=14	2018

CSNA03:461	CSNA03	operant conditioning chamber	cocaine	dose response, mean number of infusions (intravenous self administration) on last two stabilized sessions, CC [n] infusions_cc 110391 mg/kg: 1.0 1.8 0.56 0.32 0.1 0.18 0.056 0.032 1.0 (2nd)	CC w/par	57	both	4-25wks	N=6	2018

CSNA03:470	CSNA03	operant conditioning chamber	cocaine	dose response, mean number of infusions (intravenous self administration) on last two stabilized sessions, DO [n] infusions_do 110262 mg/kg: 1.0 1.8 0.56 0.32 0.1 0.18 0.056 0.032 1.0 (2nd)	DO population w/par	9	both	4-25wks	N=73	2018

CSNA03:533	CSNA03	operant conditioning chamber	cocaine	reinstatement, active lever presses (intravenous self administration), founders [n] reinstatement_active_in 110216 session: 1 2	inbred w/CC8	7	both	4-25wks	N=7	2018

CSNA03:623	CSNA03	operant conditioning chamber	(none)	total number of anticipatory responses in left flanking hole without prior successful nose poke in central hole (reversal learning assay), founders [n] antici_resp_left_in_JAX 110479 acquisition reversal	inbred w/CC8	8	both	4-25wks	N=7	2018

CSNA03:625	CSNA03	operant conditioning chamber	(none)	total number of anticipatory responses in left flanking hole without prior successful nose poke in central hole (reversal learning assay), CC [n] antici_resp_left_cc_JAX 110509 acquisition reversal	CC w/par	52	both	4-25wks	N=3	2018

CSNA03:627	CSNA03	operant conditioning chamber	(none)	total number of anticipatory responses in left flanking hole without prior successful nose poke in central hole (reversal learning assay), DO [n] antici_resp_left_do_JAX 110539 acquisition reversal	DO population w/par	9	both	4-25wks	N=28	2018

CSNA03:629	CSNA03	operant conditioning chamber	(none)	total number of anticipatory responses in right flanking hole without prior successful nose poke in central hole (reversal learning assay), founders [n] antici_resp_right_in_JAX 110481 acquisition reversal	inbred w/CC8	8	both	4-25wks	N=7	2018

CSNA03:631	CSNA03	operant conditioning chamber	(none)	total number of anticipatory responses in right flanking hole without prior successful nose poke in central hole (reversal learning assay), CC [n] antici_resp_right_cc_JAX 110511 acquisition reversal	CC w/par	52	both	4-25wks	N=3	2018

CSNA03:633	CSNA03	operant conditioning chamber	(none)	total number of anticipatory responses in right flanking hole without prior successful nose poke in central hole (reversal learning assay), DO [n] antici_resp_right_do_JAX 110541 acquisition reversal	DO population w/par	9	both	4-25wks	N=28	2018

CSNA03:635	CSNA03	operant conditioning chamber	(none)	mean number of anticipatory nose pokes made in correct flanking hole without prior successful nose poke in central hole (reversal learning assay), founders [n] antici_correct_in_JAX 110483 acquisition reversal	inbred w/CC8	8	both	4-25wks	N=7	2018

CSNA03:637	CSNA03	operant conditioning chamber	(none)	mean number of anticipatory nose pokes made in correct flanking hole without prior successful nose poke in central hole (reversal learning assay), CC [n] antici_correct_cc_JAX 110513 acquisition reversal	CC w/par	52	both	4-25wks	N=3	2018

CSNA03:639	CSNA03	operant conditioning chamber	(none)	mean number of anticipatory nose pokes made in correct flanking hole without prior successful nose poke in central hole (reversal learning assay), DO [n] antici_correct_do_JAX 110543 acquisition reversal	DO population w/par	9	both	4-25wks	N=28	2018

CSNA03:641	CSNA03	operant conditioning chamber	(none)	mean number of anticipatory nose pokes made in incorrect flanking hole without prior successful nose poke in central hole (reversal learning assay), founders [n] antici_incorrect_in_JAX 110485 acquisition reversal	inbred w/CC8	8	both	4-25wks	N=7	2018

CSNA03:643	CSNA03	operant conditioning chamber	(none)	mean number of anticipatory nose pokes made in incorrect flanking hole without prior successful nose poke in central hole (reversal learning assay), CC [n] antici_incorrect_cc_JAX 110515 acquisition reversal	CC w/par	52	both	4-25wks	N=3	2018

CSNA03:645	CSNA03	operant conditioning chamber	(none)	mean number of anticipatory nose pokes made in incorrect flanking hole without prior successful nose poke in central hole (reversal learning assay), DO [n] antici_incorrect_do_JAX 110545 acquisition reversal	DO population w/par	9	both	4-25wks	N=28	2018

Deschepper1:4	Deschepper1	organ weights	(none)	ventricle weight, normalized to body weight [mg] heart_V_adj 10404 right left both	inbred	13	both	10wks	N=10	2004

DiPetrillo2:2	DiPetrillo2	urinalysis	(none)	creatinine (urine CREA) [mg/dL] CREA 46102	CC pre w/par	163	m	10wks	N=2	2012

Donahue2:1	Donahue2	body weight	(none)	whole body weight, with head [g] bw 17201	inbred	10	both	16wks	N=10	2004

Donahue2:14	Donahue2	bone dimensions	(none)	anterior to posterior, rostral to caudal, width of right femur, mid-diaphysis [mm] femur_width_AP 17214	inbred	10	both	16wks	N=10	2004

Donahue2:15	Donahue2	bone dimensions	(none)	medial to lateral width of right femur, mid-diaphysis [mm] femur_width_ML 17215	inbred	10	both	16wks	N=10	2004

Donahue2:16	Donahue2	computed tomography	(none)	cross sectional bone area, whole thigh area minus muscle area, femoral mid-diaphysis [mm²] femur_area 17216	inbred	10	both	16wks	N=10	2004

Donahue2:20	Donahue2	computed tomography	(none)	periosteal (outer) circumference, femoral mid-diaphysis [mm] femur_out 17220	inbred	10	both	16wks	N=10	2004

Donahue2:22	Donahue2	DXA	(none)	cross-sectional area of thigh muscle and bone, femoral mid-diaphysis [mm²] thigh_area 17222	inbred	10	both	16wks	N=10	2004

Donahue2:23	Donahue2	DXA	(none)	cross-sectional thigh muscle area (thigh area minus femur area), femoral mid-diaphysis [mm²] thigh_muscle_area 17223	inbred	10	both	16wks	N=10	2004

Donahue2:24	Donahue2	muscle weights	(none)	weight of isolated right quadriceps muscle [g] quadricep_wt 17224	inbred	10	both	16wks	N=10	2004

Donahue2:30	Donahue2	biomechanical test	(none)	estimated elastic modulus [N/mm²] elastic_modulus 17230	inbred	10	both	16wks	N=10	2004

GMC03:20	GMC03	observation (SHIRPA)	(none)	gait (0=fluid, 1=abnormal) [score] gait 55244	inbred w/CC8	8	both	8-10wks	N=17	2018

GMC12:12	GMC12	echocardiography	(none)	heart rate, beats per min [n/min] heart_rate 56112	inbred w/CC8	8	both	14-15wks	N=17	2018

GMC12:22	GMC12	echocardiography	(none)	fractional shortening [%] fract_shortening 56122	inbred w/CC8	8	both	14-15wks	N=17	2018

GMC12:23	GMC12	echocardiography	(none)	ejection fraction [%] EJ_fraction 56123	inbred w/CC8	8	both	14-15wks	N=17	2018

GMC12:33	GMC12	echocardiography	(none)	left ventricular internal dimension [mm] LVID 56133 diastole systole	inbred w/CC8	8	both	14-15wks	N=17	2018

Harrill2:21	Harrill2	metabolic panel	DB289	creatinine (serum CREA) [mg/dL] serum_CREA 44121 control DB289 difference	inbred	34	f	6-8wks	N=5	2012

Harrill2:51	Harrill2	organ weights	DB289	total kidney weight as percentage of body weight [%] pctKW_BW 44151 control DB289 difference	inbred	34	f	6-8wks	N=5	2012

Harrill2:65	Harrill2	organ weights	DB289	liver weight as percentage of body weight [%] pctLW_BW 44165 control DB289 difference	inbred	34	f	6-8wks	N=5	2012

Hawes1:20	Hawes1	ophthalmoscopy	(none)	retinal hypopigmentation [frequency rate] ret_hypopig 26720	inbred w/CC7	40	both	6-7wks	N=10	2008

Loos2:26	Loos2	home cage monitoring	(none)	change in Spout zone duration: anticipation of phase change, over 3 days of testing spout_anticipation 54026 dark light	inbred w/CC7	11	m	8-12wks	N=35	2016

Loos2:36	Loos2	home cage monitoring	(none)	change in OnShelter zone duration: anticipation of phase change, over 3 days of testing onshelter_anticipation 54036 dark light	inbred w/CC7	11	m	8-12wks	N=35	2016

Loos2:71	Loos2	home cage monitoring	(none)	cumulative number of long shelter visits (sheltering), over 3 days of testing, log10 transformed [log(n)] long_shelter_num 54071 dark light	inbred w/CC7	11	m	8-12wks	N=40	2016

Odet2:21	Odet2	microscopy	(none)	percentage of motile sperm that are 'intermediate' [%] sperm_int 53821 min: 10 30 60 90 120	inbred w/CC8	8	m	10-66wks	N=13	2015

Odet2:75	Odet2	microscopy	(none)	sperm mean lateral head displacement (amplitude) [µm] sperm_ALH 53875 min: 10 30 60 90 120	inbred w/CC8	8	m	10-66wks	N=13	2015

Odet2:81	Odet2	microscopy	(none)	sperm mean cross beat frequency [Hz] sperm_BCF 53881 min: 10 30 60 90 120	inbred w/CC8	8	m	10-66wks	N=13	2015

Peters1:14	Peters1	complete blood count	(none)	eosinophil differential (percent of total WBC) [%] EOS 6214	inbred w/CC7	43	both	10wks	N=11	2001

Project1003:3	Project1003	immunoglobulin quantification	(none)	anti-filamentous hemagglutinin antibodies (Log) [U/mL] FHA 110003	inbred	28	f	14wks	N=8	2019

Project1003:4	Project1003	immunoglobulin quantification	(none)	anti-pertactin antibodies (Log) [U/mL] Prn 110004	inbred	28	f	14wks	N=8	2019

Project1003:5	Project1003	immunoglobulin quantification	(none)	anti-tetanus toxoid antibodies (Log) [U/mL] TT 110005	inbred	28	f	14wks	N=8	2019

Project1099:3	Project1099	None	(none)	Unnamed__4 Unnamed__4 114138	inbred w/CC8	9	both		N=24	2022

Project1099:9	Project1099	None	(none)	Min_Depression_BR____ Min_Depression_BR____ 114144	inbred w/CC8	9	both		N=25	2022

Project1162:45	Project1162	None	(none)	Min_Depression_BR____ Min_Depression_BR____ 118458 0.63 mg/kg 6.4 mg/kg 8 mg/kg 17 mg/kg 24 mg/kg 33 mg/kg 40 mg/kg 50 mg/kg (4 more)...	inbred w/CC8	9	both		N=6	2022

Project1217:5	Project1217	None	(none)	pH pH 131754 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:13	Project1217	None	(none)	PAO2 PAO2 131762 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:17	Project1217	None	(none)	pCO2 pCO2 131766 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:29	Project1217	None	(none)	sO2 sO2 131778 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:33	Project1217	None	(none)	O2Hb O2Hb 131782 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:41	Project1217	None	(none)	RHb RHb 131790 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:69	Project1217	None	(none)	Lac Lac 131818 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:73	Project1217	None	(none)	tO2 tO2 131822 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:105	Project1217	None	(none)	PAU PAU 131854 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:129	Project1217	None	(none)	Te Te 131878 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:141	Project1217	None	(none)	EEP EEP 131890 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Project1217:153	Project1217	None	(none)	TP TP 131902 Baseline T0-T15 T15-T30 T30-T45	other	8	both		N=7	2024

Schughart3:11	Schughart3	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 10 FFU group [%] pctbwA 57111 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14	inbred w/CC8	8	both	7-13wks	N=9	2013

Schughart4:11	Schughart4	body weight	(none)	body weight as percent of baseline, control (saline) group [%] pctbw_ctrl 58711 days post-treatment (saline): 1 2 3	inbred w/CC8	8	f	8-12wks	N=6	2016

Schughart4:21	Schughart4	body weight	influenza A (H3N2) virus	body weight as percent of baseline, infected group [%] pctbw_trt 58721 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 18 30	inbred w/CC8	8	f	8-12wks	N=11	2016

Schughart4:43	Schughart4	complete blood count	influenza A (H3N2) virus	white blood cell count (WBC; per volume x 10³), treated group [n/µL] WBC_trt 58743 days post-infection: 3 5 8 18 30	inbred w/CC8	8	f	8-12wks	N=6	2016

Schughart4:83	Schughart4	in vitro assay	influenza A (H3N2) virus	viral load in lungs (titer, FFU per lung) log10 (x+1) [log(n)] titer_trt 58783 days post-infection: 3 5 8	inbred w/CC8	8	f	8-12wks	N=5	2016

Shimomura2:21	Shimomura2	monitoring system	(none)	phase angle of entrainment [h] phase_angle 52721	inbred w/CC7	38	both	10wks	N=8	2015

Tordoff3:8	Tordoff3	bottle choice test	(none)	preference for CaCl2 (calcium chloride) solutions [%] CaCl2_pref 10308 concentration (mM): 7.5 25 75	inbred w/CC7	40	both	9-11wks	N=10	2002

Tordoff3:11	Tordoff3	bottle choice test	(none)	preference for CaLa (calcium lactate) solutions [%] CaLa_pref 10311 concentration (mM): 7.5 25 75	inbred w/CC7	40	both	10-12wks	N=10	2002

Wiltshire4:53	Wiltshire4	immune cell quantification	idarubicin	monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

List measures where PWK/PhJ is an outlier

Filter Table Results